FREMAUX, Juliette; VENIN, Claire; MAURAN, Laura; ZIMMER, Robert H.; GUICHARD, Gilles; GOUDREAU, Sébastien R.

doi:10.1038/s41467-019-08793-y

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Nature Communications. 2019, vol. 10, n° 1, p. 924

Résumé en anglais

Peptides have gained so much attention in the last decade that they are now part of the main strategies, with small molecules and biologics, for developing new medicines. Despite substantial progress, the successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability. Here, we describe the use of oligourea foldamers as tool to improve the pharmaceutical properties of GLP-1, a 31 amino acid peptide hormone involved in metabolism and glycemic control. Our strategy consists in replacing four consecutive amino acids of GLP-1 by three consecutive ureido residues by capitalizing on the structural resemblance of oligourea and α-peptide helices. The efficacy of the approach is demonstrated with three GLP-1-oligourea hybrids showing prolonged activity in vivo. Our findings should enable the use of oligoureas in other peptides to improve their pharmaceutical properties and may provide new therapeutic applications.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Lien vers les données de la recherche

Unités de recherche